Insights & news

Swiss Competition Authority Carries out Dawn Raid in Probe regarding Possible Abuse of Patent Rights

  • 15/09/2022
  • News

On Tuesday 13 September, the Swiss Competition Authority carried out a dawn raid to collect evidence in a probe regarding a possible abuse of a dominant position in relation to dermatological medication (see, today’s attached press release in three languages). According to press reports, Novartis acknowledged to be the target of the investigation.
 
The inquiry focuses on the possibly abusive initiation of patent litigation to thwart competing products. The press release refers to the use of a “blocking patent” which may mean the deployment of a patent to prevent another patent from being used because that other patent relies on technology covered by the first. The Swiss Competition Authority’s move is unusual in that exercising valid patent rights does not normally amount to an abuse of a dominant position.
 
The Swiss Competition Authority says it has cooperated on this matter with the European Commission pursuant to the bilateral agreement between the European Union and Switzerland on the application of the competition rules.

Key contacts

Related insights

Sign up for updates
    • 16/09/2022
    • News

    Belgium Eases Conditions for Parallel Imports of Pharmaceuticals

    Today, 16 September 2022, marks the entry into force of a Royal Decree of 4 September 2022 "amending the Royal Decree of 19 April 2001 on the parallel import of medicines for human use and the parallel distribution of medicines for human and veterinary use" (the RD; see attached copy). The RD was published in the Belgian Official Journal on 15 September 2022.

    Read more
    • 07/09/2022
    • News

    European Commission Prohibits Acquisition of Grail by Illumina

    On 6 September 2022, the European Commission (the Commission) prohibited the acquisition of cancer detection test start-up Grail by genetic and genomic analysis firm Illumina.

    Read more
    • 02/09/2022
    • News

    European Union Medical Device Coordination Group Publishes List of Action Items

    Back in June 2022, EU Health Ministers expressed concern that innovative medical devices would be delayed in reaching the market and that, generally, the supply of medical devices would be disrupted. In response, the Medical Device Coordination Group (MDCG), an advisory and coordinating body of Member State representatives responsible for administering Regulation (EU) 2017/45 governing medical devices (MDR) and Regulation (EU) 2017/46 governing in vitro diagnostic medical devices (IVDR), produced at the end of August 2022 a list of action items to make the most of the transition periods which both the MDR and the IVDR provide for (see, attached MDCG Position Paper 2022-14). The MDCG stresses that its measures are designed to improve the efficiency of the new regulatory framework, rather than alleviate its requirements, and that they will certainly not be implemented at the expense of the devices’ safety.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *